Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel

George Umanah, Marco Pignatelli, Xiling Yin, Rong Chen, Joshua Crawford, Stewart Neifert, Leslie Scarffe, Adam A. Behensky, Noah Guiberson, Melissa Chang, Erica Ma, Jin Wan Kim, Cibele C. Castro, Xiaobo Mao, Li Chen, Shaida A. Andrabi, Mikhail Pletnikov, Ann E Pulver, Dimitrios Avramopoulos, Antonello BonciDavid Valle, Ted M Dawson, Valina Dawson

Research output: Contribution to journalArticle

Abstract

The AAA+ adenosine triphosphatase (ATPase) Thorase plays a critical role in controlling synaptic plasticity by regulating the expression of surface a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants. These variants caused defects in glutamatergic signaling by impairing AMPAR internalization and recycling in mouse primary cortical neurons. This contributed to increased surface expression of the AMPAR subunit GluA2 and enhanced synaptic transmission. Heterozygous Thorase-deficient mice engineered to express these Thorase variants showed altered synaptic transmission and several behavioral deficits compared to heterozygous Thorase-deficient mice expressing wild-type Thorase. These behavioral impairments were rescued by the competitive AMPAR antagonist Perampanel, a U.S. Food and Drug Administration-approved drug. These findings suggest that Perampanel may be useful for treating disorders involving compromised AMPAR-mediated glutamatergic neurotransmission.

Original languageEnglish (US)
Article numberaah4985
JournalScience Translational Medicine
Volume9
Issue number420
DOIs
StatePublished - Dec 13 2017

Fingerprint

Synaptic Transmission
Acids
Neuronal Plasticity
United States Food and Drug Administration
Adenosine Triphosphatases
Exons
Schizophrenia
perampanel
Neurons
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. / Umanah, George; Pignatelli, Marco; Yin, Xiling; Chen, Rong; Crawford, Joshua; Neifert, Stewart; Scarffe, Leslie; Behensky, Adam A.; Guiberson, Noah; Chang, Melissa; Ma, Erica; Kim, Jin Wan; Castro, Cibele C.; Mao, Xiaobo; Chen, Li; Andrabi, Shaida A.; Pletnikov, Mikhail; Pulver, Ann E; Avramopoulos, Dimitrios; Bonci, Antonello; Valle, David; Dawson, Ted M; Dawson, Valina.

In: Science Translational Medicine, Vol. 9, No. 420, aah4985, 13.12.2017.

Research output: Contribution to journalArticle

Umanah, G, Pignatelli, M, Yin, X, Chen, R, Crawford, J, Neifert, S, Scarffe, L, Behensky, AA, Guiberson, N, Chang, M, Ma, E, Kim, JW, Castro, CC, Mao, X, Chen, L, Andrabi, SA, Pletnikov, M, Pulver, AE, Avramopoulos, D, Bonci, A, Valle, D, Dawson, TM & Dawson, V 2017, 'Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel', Science Translational Medicine, vol. 9, no. 420, aah4985. https://doi.org/10.1126/scitranslmed.aah4985
Umanah, George ; Pignatelli, Marco ; Yin, Xiling ; Chen, Rong ; Crawford, Joshua ; Neifert, Stewart ; Scarffe, Leslie ; Behensky, Adam A. ; Guiberson, Noah ; Chang, Melissa ; Ma, Erica ; Kim, Jin Wan ; Castro, Cibele C. ; Mao, Xiaobo ; Chen, Li ; Andrabi, Shaida A. ; Pletnikov, Mikhail ; Pulver, Ann E ; Avramopoulos, Dimitrios ; Bonci, Antonello ; Valle, David ; Dawson, Ted M ; Dawson, Valina. / Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. In: Science Translational Medicine. 2017 ; Vol. 9, No. 420.
@article{9a2b5f36dbe9457da91ccbcec9266195,
title = "Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel",
abstract = "The AAA+ adenosine triphosphatase (ATPase) Thorase plays a critical role in controlling synaptic plasticity by regulating the expression of surface a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants. These variants caused defects in glutamatergic signaling by impairing AMPAR internalization and recycling in mouse primary cortical neurons. This contributed to increased surface expression of the AMPAR subunit GluA2 and enhanced synaptic transmission. Heterozygous Thorase-deficient mice engineered to express these Thorase variants showed altered synaptic transmission and several behavioral deficits compared to heterozygous Thorase-deficient mice expressing wild-type Thorase. These behavioral impairments were rescued by the competitive AMPAR antagonist Perampanel, a U.S. Food and Drug Administration-approved drug. These findings suggest that Perampanel may be useful for treating disorders involving compromised AMPAR-mediated glutamatergic neurotransmission.",
author = "George Umanah and Marco Pignatelli and Xiling Yin and Rong Chen and Joshua Crawford and Stewart Neifert and Leslie Scarffe and Behensky, {Adam A.} and Noah Guiberson and Melissa Chang and Erica Ma and Kim, {Jin Wan} and Castro, {Cibele C.} and Xiaobo Mao and Li Chen and Andrabi, {Shaida A.} and Mikhail Pletnikov and Pulver, {Ann E} and Dimitrios Avramopoulos and Antonello Bonci and David Valle and Dawson, {Ted M} and Valina Dawson",
year = "2017",
month = "12",
day = "13",
doi = "10.1126/scitranslmed.aah4985",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "420",

}

TY - JOUR

T1 - Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel

AU - Umanah, George

AU - Pignatelli, Marco

AU - Yin, Xiling

AU - Chen, Rong

AU - Crawford, Joshua

AU - Neifert, Stewart

AU - Scarffe, Leslie

AU - Behensky, Adam A.

AU - Guiberson, Noah

AU - Chang, Melissa

AU - Ma, Erica

AU - Kim, Jin Wan

AU - Castro, Cibele C.

AU - Mao, Xiaobo

AU - Chen, Li

AU - Andrabi, Shaida A.

AU - Pletnikov, Mikhail

AU - Pulver, Ann E

AU - Avramopoulos, Dimitrios

AU - Bonci, Antonello

AU - Valle, David

AU - Dawson, Ted M

AU - Dawson, Valina

PY - 2017/12/13

Y1 - 2017/12/13

N2 - The AAA+ adenosine triphosphatase (ATPase) Thorase plays a critical role in controlling synaptic plasticity by regulating the expression of surface a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants. These variants caused defects in glutamatergic signaling by impairing AMPAR internalization and recycling in mouse primary cortical neurons. This contributed to increased surface expression of the AMPAR subunit GluA2 and enhanced synaptic transmission. Heterozygous Thorase-deficient mice engineered to express these Thorase variants showed altered synaptic transmission and several behavioral deficits compared to heterozygous Thorase-deficient mice expressing wild-type Thorase. These behavioral impairments were rescued by the competitive AMPAR antagonist Perampanel, a U.S. Food and Drug Administration-approved drug. These findings suggest that Perampanel may be useful for treating disorders involving compromised AMPAR-mediated glutamatergic neurotransmission.

AB - The AAA+ adenosine triphosphatase (ATPase) Thorase plays a critical role in controlling synaptic plasticity by regulating the expression of surface a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants. These variants caused defects in glutamatergic signaling by impairing AMPAR internalization and recycling in mouse primary cortical neurons. This contributed to increased surface expression of the AMPAR subunit GluA2 and enhanced synaptic transmission. Heterozygous Thorase-deficient mice engineered to express these Thorase variants showed altered synaptic transmission and several behavioral deficits compared to heterozygous Thorase-deficient mice expressing wild-type Thorase. These behavioral impairments were rescued by the competitive AMPAR antagonist Perampanel, a U.S. Food and Drug Administration-approved drug. These findings suggest that Perampanel may be useful for treating disorders involving compromised AMPAR-mediated glutamatergic neurotransmission.

UR - http://www.scopus.com/inward/record.url?scp=85038433724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038433724&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aah4985

DO - 10.1126/scitranslmed.aah4985

M3 - Article

C2 - 29237760

AN - SCOPUS:85038433724

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 420

M1 - aah4985

ER -